Lytix Biopharma Share Price

Equities

LYTIX

NO0010405780

Biotechnology & Medical Research

Market Closed - Oslo Bors 15:45:00 26/04/2024 BST 5-day change 1st Jan Change
5.72 NOK -1.04% Intraday chart for Lytix Biopharma +7.92% +17.70%

Financials

Sales 2023 - Sales 2024 * 6.3M 571K 45.71M Capitalization 229M 20.79M 1.66B
Net income 2023 -87 -7.89 -631.2 Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * 49.6M 4.5M 360M Net cash position 2024 * 61.8M 5.61M 448M EV / Sales 2024 * 26.6 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 8
Yield 2023 *
-
Yield 2024 *
-
Free-Float 53.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.04%
1 week+7.92%
Current month-6.23%
1 month-9.21%
3 months-23.22%
6 months-8.48%
Current year+17.70%
More quotes
1 week
5.16
Extreme 5.16
6.80
1 month
5.16
Extreme 5.16
6.90
Current year
4.64
Extreme 4.64
8.80
1 year
4.60
Extreme 4.6
14.40
3 years
4.60
Extreme 4.6
21.50
5 years
4.60
Extreme 4.6
21.50
10 years
4.60
Extreme 4.6
21.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - 31/12/02
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 31/12/07
Members of the board TitleAgeSince
Director/Board Member 64 06/06/21
Director/Board Member 66 06/06/21
Director/Board Member 48 06/06/21
More insiders
Date Price Change Volume
26/04/24 5.72 -1.04% 113,426
25/04/24 5.78 +7.04% 204,090
24/04/24 5.4 +0.75% 14,221
23/04/24 5.36 -3.60% 85,174
22/04/24 5.56 +4.91% 12,663

Real-time Oslo Bors, April 26, 2024 at 03:45 pm

More quotes
Lytix Biopharma AS is a Norway-based company engaged in biotechnology. The Company is involved in development, marketing and sales of pharmaceutical and biotechnology products, as well as related activities. Lytix Biopharma AS developing cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lytix Biopharma molecules kill cancer cells, including resistant cells, and expose their internal components to the immune system. This results in uptake of tumor antigens and activation of tumor antigen-presenting cells, thereby generating a broad and long-lasting systemic T-cell response that overcomes tumor heterogeneity. Lytix Biopharma molecules can work in a wide variety of cancer indications and settings, both as mono- and combination therapies.
Calendar
More about the company

Chiffre d''affaires - Rate of surprise